Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013:119:51-83.
doi: 10.1016/B978-0-12-407707-2.00002-3.

Residual immune dysregulation syndrome in treated HIV infection

Michael M Lederman  1 , Nicholas T Funderburg, Rafick P Sekaly, Nichole R Klatt, Peter W Hunt
Affiliations
Review

Residual immune dysregulation syndrome in treated HIV infection

Michael M Lederman et al. Adv Immunol. 2013.

Abstract

Antiretroviral therapy has revolutionized the course of HIV infection, improving immune function and decreasing dramatically the mortality and morbidity due to the opportunistic complications of the disease. Nonetheless, even with sustained suppression of HIV replication, many HIV-infected persons experience a syndrome characterized by increased T cell activation and evidence of heightened inflammation and coagulation. This residual immune dysregulation syndrome or RIDS is more common in persons who fail to increase circulating CD4+ T cells to normal levels and in several epidemiologic studies it has been associated with increased morbidity and mortality. These morbid and fatal events are not the typical opportunistic infections and malignancies seen in the early AIDS era but rather comprise a spectrum of cardiovascular events, liver disease, metabolic disorders, kidney disease, bone disease, and a spectrum of malignant complications distinguishable from the opportunistic malignancies that characterized the earlier days of the AIDS epidemic. While immune activation, inflammation, and coagulopathy are characteristic of untreated HIV infection and improve with drug-induced control of HIV replication, the drivers of RIDS in treated HIV infection are incompletely understood. And while inflammation, immune activation, and coagulopathy are more common in treated persons who fail to restore circulating CD4+ T cells, it is not entirely clear how these two phenomena are linked.

Keywords: Antiretroviral therapy; CD 127; CD14; CD163; CD38; Cell cycling; Coagulation; Cycling D-dimer; Gut-associated lymphoid tissue; HLA-DR; Immune activation; Immune failure; Indoleamine 2,3-dioxygenase; Inflammation; Interleukin-6 (IL-6); Lipopolysaccharide; Lymph node; Microbial translocation; Residual immune dysregulation syndrome.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, et al. Interleukin-2 therapy in patients with HIV infection. The New England Journal of Medicine. 2009;361(16):1548–1559. http://dx.doi.org/10.1056/NEJMoa0903175. - DOI - PMC - PubMed
    1. Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS. 2010;24(12):1877–1886. http://dx.doi.org/QAI.0b013e31823fd1f2/QAD.0b013e32833b1b2. - PMC - PubMed
    1. Andersson J, Fehniger TE, Patterson BK, Pottage J, Agnoli M, Jones P, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS. 1998;12(11):F123–F129. - PubMed
    1. Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, et al. Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS. 2003;17(1):53–63. - PubMed
    1. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nature Immunology. 2008;9(3):301–309. http://dx.doi.org/10.1038/ni1566. - DOI - PubMed

Publication types

Substances